EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
Public ClinicalTrials.gov record NCT01485848. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objectives: o Run-in Phase: Determine a dose of EP-100 at which the initial benefit/risk of paclitaxel combined with EP-100 can be studied. o Randomized Phase: Compare the anti-tumor effects of EP-100 combined with weekly paclitaxel versus paclitaxel alone in patients with ovarian cancer. Secondary Objectives: o Randomized Phase: Quantify any significant changes in the safety profile of weekly paclitaxel alone compared to the doublet combination of paclitaxel with EP-100. o Determine an initial benefit/risk profile for this new drug combination.
Study identification
- NCT ID
- NCT01485848
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 49 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2012 (Type not available)
- Primary completion
- May 2014 (Actual)
- Completion
- May 2014 (Actual)
- Last update posted
- Jun 10, 2014
2012 – 2014
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840001 | Greenbrae | California | 94904-2011 | — |
| Investigational Site Number 840005 | San Francisco | California | 94115 | — |
| Investigational Site Number 840007 | Louisville | Kentucky | 40202 | — |
| Investigational Site Number 840010 | Covington | Louisiana | 70433 | — |
| Investigational Site Number 840011 | Shreveport | Louisiana | 71103 | — |
| Investigational Site Number 840503 | Bozeman | Montana | 58715 | — |
| Investigational Site Number 840004 | Middletown | Ohio | 45042 | — |
| Investigational Site Number 840008 | Portland | Oregon | 97227-1191 | — |
| Investigational Site Number 840006 | Houston | Texas | 77030 | — |
| Investigational Site Number 840603 | Kennewick | Washington | 99336 | — |
| Investigational Site Number 840103 | Mount Vernon | Washington | 98273 | — |
| Investigational Site Number 840403 | Seattle | Washington | 98112 | — |
| Investigational Site Number 840003 | Seattle | Washington | 98115 | — |
| Investigational Site Number 840303 | Tacoma | Washington | 98415-0299 | — |
| Investigational Site Number 840203 | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01485848, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2014 · Synced Oct 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01485848 live on ClinicalTrials.gov.